Neuronal imaging using SPECT

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 6, 2007, Pages 939-950

  Yamashina, Shohei ^a   Yamazaki, Jun Ichi ^a  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

123I MIBG; Cardiac disease; Planar; SPECT; Sympathetic nervous system

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 123; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPALRESTAT; IODINE 123; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; METOPROLOL; NICORANDIL; PERINDOPRIL; RESERPINE; SPIRONOLACTONE; TETROFOSMIN TC 99M; TITANIUM; VALSARTAN;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ALZHEIMER DISEASE; AMYLOIDOSIS; ANGINA PECTORIS; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; DEMENTIA; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART GRAFT; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PERFUSION; HEART SCINTISCANNING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; PARKINSON DISEASE; PARKINSONISM; PROGNOSIS; PULMONARY HYPERTENSION; Q WAVE; QUANTITATIVE ANALYSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC FUNCTION; SYMPATHETIC NERVE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; VALVULAR HEART DISEASE;

3-IODOBENZYLGUANIDINE; ARRHYTHMIA; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; IODINE RADIOISOTOPES; MODELS, CHEMICAL; MYOCARDIUM; NEURONS; NOREPINEPHRINE; RADIOPHARMACEUTICALS; RISK; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34249018280     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0359-0     Document Type: Review

References (89)

1. 131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53.
2. Tobes MC, Jaques S Jr, Wieland DM, Sisson JC. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med 1985;26:897-907.
3. Nakajo M, Shimabukuro K, Yoshimura H, Yonekura R, Nakabeppu Y, Tanoue P, et al. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med 1986;27:84-9.
4. Sisson JC, Wieland DM, Sherman P, Mangner TJ, Tobes MC, Jacques S Jr. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 1987;28:1620-4.
5. 131I] meta-iodobenzylguanidine: concise communication. J Nucl Med 1981;22:358-64.
6. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981;22:22-31.
7. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513-21.
8. Gill JS, Hunter GJ, Gane G, Camm AJ. Heterogeneity of the human myocardial sympathetic innervation: in vivo demonstration by iodine 123-labeled meta-iodobenzylguanidine scintigraphy. Am Heart J 1993;126:390-8.
9. Estorch M, Carrió I, Berna L, Lopez-Pousa J, Torres G. Myocardial iodine-labeled metaiodobenzylguanidine 123 uptake relates to age. J Nucl Cardiol 1995;2:126-32.
10. Tsuchimochi S, Tamaki N, Tadamura E, Kawamoto M, Fujita T, Yonekura Y, et al. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging. J Nucl Med 1995;36:969-74.
11. Rabinovitch MA, Rose CP, Schwab AJ, Fitchett DH, Honos GN, Stewart JA, et al. A method of dynamic analysis of iodine-123-metaiodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure. J Nucl Med 1993;34:589-600.
12. Somsen GA, Borm JJ, de Milliano PA, van Vlies B, Dubois EA, van Royen EA. Quantitation of myocardial iodine-123 MIBG uptake in SPET studies: a new approach using the left ventricular cavity and a blood sample as a reference. Eur J Nucl Med 1995;22:1149-54.
13. Taki J, Yasuhara S, Takamatsu T, Nakaji2ma K, Tatami R, Ishise S, et al. Value of iodine-123 metaiodobenzylguanidine scintigraphy in patients with vasospastic angina. Eur J Nucl Med 1998;25:229-34.
14. Sakata K, Iida K, Kudo M, Yoshida H, Doi O. Prognostic value of I-123 metaiodobenzylguanidine imaging in vasospastic angina without significant coronary stenosis. Circ J 2005;69:171-6.
15. Tsutsui H, Ando S, Fukai T, Kuroiwa M, Egashira K, Sasaki M, et al. Detection of angina-provoking coronary stenosis by resting iodine 123 metaiodobenzylguanidine scintigraphy in patients with unstable angina pectoris. Am Heart J 1995;129:708-15.
16. Matsunari I, Schricke U, Bengel FM, Haase HU, Barthel P, Schmidt G, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 2000;101:2579-85.
17. Simula S, Lakka T, Laitinen T, Remes J, Kettunen R, Kuikka J, et al. Cardiac adrenergic denervation in patients with non-Q-wave versus Q-wave myocardial infarction. Eur J Nucl Med 2000;27:816-21.
18. Imamura Y, Ando H, Mitsuoka W, Egashira S, Masaki H, Ashihara T, et al. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol 1995;26:1594-9.
19. Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12:1252-8.
20. Merlet P, Dubois-Rande JL, Adnot S, Bourguignon MH, Benvenuti C, Loisance D, et al. Myocardial beta-adrenergic desensitization and neuronal norepinephrine uptake function in idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 1992;19:10-6.
21. Matsuo S, Nakamura Y, Tsutamoto T, Kinoshita M. Impairments of myocardial sympathetic activity may reflect the progression of myocardial damage or dysfunction in hypertrophic cardiomyopathy. J Nucl Cardiol 2002;9:407-12.
22. Imamura Y, Ando H, Ashihara T, Fukuyama T. Myocardial adrenergic nervous activity is intensified in patients with heart failure without left ventricular volume or pressure overload. J Am Coll Cardiol 1996;28:371-5.
23. Tsutsui H, Ando S, Kubota T, Kuroiwa-Matsumoto M, Egashira K, Sasaki M, et al. Abnormalities of cardiac sympathetic neuronal and left ventricular function in chronic mitral regurgitation: assessment by iodine-123 metaiodobenzylguanidine scintigraphy. Am J Card Imaging 1996;10:14-22.
24. 123I-metaiodobenzylguanidine left ventricular imaging. J Nucl Med 2000;41:1127-33.
25. Hongo M, Urushibata K, Kai R, Takahashi W, Koizumi T, Uchikawa S, et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am Heart J 2002;144:122-9.
26. Sugiyama T, Kurata C, Tawarahara K, Nakano T. Is abnormal iodine-123-MIBG kinetics associated with left ventricular dysfunction in patients with diabetes mellitus? J Nucl Cardiol 2000;7:562-8.
27. Arimoto T, Takeishi Y, Niizeki T, Koyama Y, Okuyama H, Nozaki N, et al. Ongoing myocardial damage relates to cardiac sympathetic nervous disintegrity in patients with heart failure. Ann Nucl Med 2005;19:535-40.
28. Ohshima S, Isobe S, Izawa H, Nanasato M, Ando A, Yamada A, et al. Cardiac sympathetic dysfunction correlates with abnormal myocardial contractile reserve in dilated cardiomyopathy patients. J Am Coll Cardiol 2005;46:2061-8.
29. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.
30. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 1998;5:579-90.
31. Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K, Ehime MIBG Heart Failure Study Investigators. Prognostic value of iodine-123- metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ J 2001;65:155-60.
32. Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 2001;42:1757-67.
33. 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart 2001;86:656-60.
34. 123I-meta-iodobenzylguanidine scintigraphy and cardiac natriuretic peptides in patients with heart disease. Nucl Med Commun 2002;23:795-801.
35. Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol 2003;41:231-8.
36. Imamura Y, Fukuyama T. Prognostic value of myocardial MIBG scintigraphy findings in patients with cardiomyopathy-importance of background correction for quantification of MIBG activity. Ann Nucl Med 2002;16:387-93.
37. Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Hashimoto A, Ogata H, et al. Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction. J Card Fail 2003;9:113-21.
38. Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med 2004;45:155-63.
39. 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments-comparison with neurohumoral factors. Circ J 2002;66:537-43.
40. 123I]iodobenzylguanidine myocardial scintigraphy for predicting cardiac events in patients with dilated cardiomyopathy who receive long-term beta blocker treatment. Nucl Med Commun 2005;26:97-102.
41. 123I-MIBG scintigraphic study. J Nucl Med 2000;41:845-51.
42. Fujimura M, Yasumura Y, Ishida Y, Nakatani S, Komamura K, Yamagishi M, et al. Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. J Card Fail 2000;6:3-10.
43. 123I-metaiodobenzylguanidine uptake. J Nucl Med 2001;42:49-54.
44. Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997;38:1085-9.
45. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:574-81.
46. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 2003;44:884-90.
47. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005;45:661-7.
48. Hirooka K, Yasumura Y, Ishida Y, Hanatani A, Nakatani S, Komamura K, et al. Comparative left ventricular functional and neurohumoral effects of chronic treatment with carvedilol versus metoprolol in patients with dilated cardiomyopathy. Jpn Circ J 2001;65:931-6.
49. Toyama T, Hoshizaki H, Seki R, Isobe N, Adachi H, Naito S, et al. Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with metoprolol therapy. J Nucl Med 2003;44:1604-11.
50. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of perindopril on cardiac sympathetic nerve activity in patients with congestive heart failure: comparison with enalapril. Eur J Nucl Med Mol Imaging 2005;32:964-71.
51. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, et al. Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure. Heart 2006;92:625-30.
52. Kasama S, Toyama T, Hatori T, Kumakura H, Takayama Y, Ichikawa S, et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy. Am Heart J 2005;150:477e1-e8.
53. Kasama S, Toyama T, Kumakura H, Takayama Y, Ishikawa T, Ichikawa S, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity in patients with decompensated congestive heart failure. J Nucl Med 2004;45:1108-13.
54. Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy-clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J 2001;141:645-52.
55. Suwa M, Otake Y, Moriguchi A, Ito T, Hirota Y, Kawamura K, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J 1997;133:353-8.
56. Choi JY, Lee KH, Hong KP, Kim BT, Seo JD, Lee WR, et al. Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. J Nucl Cardiol 2001;8:4-9.
57. 123I meta-iodobenzylguanidine imaging in predicting the effectiveness of beta blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment. Heart 1999;81:148-52.
58. Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging 2005;32:186-94.
59. 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of beta-blockers in patients with dilated cardiomyopathy from the standpoint of long-term prognosis. Eur J Nucl Med Mol Imaging 2004;31:1356-61.
60. Terai H, Shimizu M, Ino H, Yamaguchi M, Uchiyama K, Oe K, et al. Changes in cardiac sympathetic nerve innervation and activity in pathophysiologic transition from typical to end-stage hypertrophic cardiomyopathy. J Nucl Med 2003;44:1612-7.
61. 123I-MIBG reflects left ventricular functional reserve in patients with nonobstructive hypertrophic cardiomyopathy. J Nucl Med 2005;46:909-16.
62. Shimizu M, Ino H, Yamaguchi M, Terai H, Hayashi K, Nakajima K, et al. Heterogeneity of cardiac sympathetic nerve activity and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Nucl Med 2002;43:15-20.
63. Terai H, Shimizu M, Ino H, Yamaguchi M, Hayashi K, Sakata K, et al. Cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy with malignant ventricular tachyarrhythmias. J Nucl Cardiol 2003;10:304-10.
64. Hiasa G, Hamada M, Saeki H, Ogimoto A, Ohtsuka T, Hara Y, et al. Cardiac sympathetic nerve activity can detect congestive heart failure sensitively in patients with hypertrophic cardiomyopathy. Chest 2004;126:679-86.
65. Dae MW, De Marco T, Botvinick EH, O'Connell JW, Hattner RS, Huberty JP, et al. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts-implications for clinical studies. J Nucl Med 1992;33:1444-50.
66. De Marco T, Dae M, Yuen-Green MS, Kumar S, Sudhir K, Keith F, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of the transplanted human heart: evidence for late reinnervation. J Am Coll Cardiol 1995;25:927-31.
67. Guertner C, Krause BJ, Klepzig H Jr, Herrmann G, Lelbach S, Vockert EK, et al. Sympathetic re-innervation after heart transplantation: dual-isotope neurotransmitter scintigraphy, norepinephrine content and histological examination. Eur J Nucl Med 1995;22:443-52.
68. Mabuchi M, Imamura M, Kubo N, Morita K, Noriyasu K, Tsukamoto T, et al. Sympathetic denervation and reinnervation after the maze procedure. J Nucl Med 2005;46:1089-94.
69. 201TlCl, magnetic resonance imaging and ultrafast computed tomography. Ann Nucl Med 1997;11:233-41.
70. Lerch H, Bartenstein P, Wichter T, Hindricks G, Borggrefe M, Breithardt G, et al. Sympathetic innervation of the left ventricle is impaired in arrhythmogenic right ventricular disease. Eur J Nucl Med 1993;20:207-12.
71. 123I-meta- iodobenzylguanidine scintigraphy. Circulation 1994;89:667-83.
72. Gohl K, Feistel H, Weikl A, Bachmann K, Wolf F. Congenital myocardial sympathetic dysinnervation (CMSD)-a structural defect of idiopathic long QT syndrome. Pacing Clin Electrophysiol 1991;14:1544-53.
73. Wichter T, Matheja P, Eckardt L, Kies P, Schafers K, Schulze-Bahr E, et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation 2002;105:702-6.
74. Gianni M, Dentali F, Grandi AM, Sumner G, Hiralal R, Lonn E. Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. Eur Heart J 2006;27:1523-9.
75. 99mTc-PYP myocardial SPECT. Ann Nucl Med 2005;19:435-45.
76. 123I-MIBG myocardial scintigraphy in patients with "takotsubo" cardiomyopathy. J Nucl Med 2004;45:1121-7.
77. Hattori N, Tamaki N, Hayashi T, Masuda I, Kudoh T, Tateno M, et al. Regional abnormality of iodine-123-MIBG in diabetic hearts. J Nucl Med 1996;37:1985-90.
78. 123I-MIBG. Diabetes Nutr Metab 2000;13:350-5.
79. Schnell O, Hammer K, Muhr-Becker D, Ziegler A, Weiss M, Tatsch K, et al. Cardiac sympathetic dysinnervation in type 2 diabetes mellitus with and without ECG-based cardiac autonomic neuropathy. J Diabetes Complications 2002;16:220-7.
80. Utsunomiya K, Narabayashi I, Tamura K, Nakatani Y, Saika Y, Onishi S, et al. Effects of aldose reductase inhibitor and vitamin B12 on myocardial uptake of iodine-123 metaiodobenzylguanidine in patients with non-insulin-dependent diabetes mellitus. Eur J Nucl Med 1998;25:1643-8.
81. Utsunomiya K, Narabayashi I, Nakatani Y, Tamura K, Onishi S. I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy. Clin Nucl Med 1999;24:418-20.
82. 123I-MIBG myocardial scintigraphical analysis in patients with and without autonomic disorder. Clin Neurol 1994;34:402-4.
83. Hishikawa N, Hashizume Y, Yoshida M, Sobue G. Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol (Berl) 2003;105:341-50.
84. 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med 2004;18:453-61.
85. 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease. J Neurol Sci 2006;240:15-9.
86. 123I-metaiodobenzylguanidine myocardial scintigraphy in heart failure. Kaku Igaku 1997;34:1139-48.
87. 123I imaging. Kaku Igaku 1999;36:997-1005.
88. Kobayashi H, Momose M, Kanaya S, Kondo C, Kusakabe K, Mitsuhashi N. Scatter correction by two-window method standardizes cardiac I-123 MIBG uptake in various gamma camera systems. Ann Nucl Med 2003;17:309-13.
89. Tamaki N, Kusakabe K, Kubo A, Kumazaki T, Shimamoto K, Senda S, et al. Guidelines for clinical use of cardiac nuclear medicine (JSC2005). Circ J 2005;69 Suppl 4:1125-202.